<SEC-DOCUMENT>0001144204-15-061678.txt : 20151030
<SEC-HEADER>0001144204-15-061678.hdr.sgml : 20151030
<ACCEPTANCE-DATETIME>20151029193451
ACCESSION NUMBER:		0001144204-15-061678
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20151028
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151030
DATE AS OF CHANGE:		20151029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		151185064

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v423284_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section&nbsp;13 or 15(d) of
the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date of Report (Date of Earliest Event Reported):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 28, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt">STAAR Surgical
Company</FONT><BR>
<FONT STYLE="font-size: 10pt">__________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Delaware</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>0-11634</U></FONT></TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>95-3797439</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>1911 Walker Ave, Monrovia, California</U></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-decoration: underline; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>91016</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registrant&rsquo;s telephone number, including area code:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">626-303-7902</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.4pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 28, 2015, the Company held a
conference call to discuss the financial results for the quarter ended October 2, 2015. A transcript of the conference call is
furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information furnished herewith pursuant
to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &ldquo;filed&rdquo; for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless
of any general incorporation language in the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 85%; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Transcript of conference call of the Company held on October 28, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">STAAR Surgical Company&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">October 29, 2015</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 82%; text-decoration: underline"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>/s/ Caren Mason</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Caren Mason</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v423284_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Event Name: Q3 2015 STAAR Surgical Co Earnings Call</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Event Date: 2015-10-28 / 4:30 pm ET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+++ presentation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operator^ Good day, ladies and gentlemen. Thank you for standing
by. Welcome to STAAR Surgical's Third Quarter 2015 Financial Results Conference Call. (Operator Instructions) This call is being
recorded today, Wednesday, October 28, 2015. At this time, I would like to turn the conference over to Mr. Brian Moore with EVC
Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brian Moore^ Thank you, Operator, and good afternoon, everyone.
Thank you for joining us on the STAAR Surgical conference call this afternoon to review the Company's financial results for the
third quarter, which ended on October 2, 2015. Joining me on the call today are Caren Mason, President and CEO of STAAR Surgical,
and Steve Brown, CFO. The news release detailing the third quarter results was issued just after 4 PM Eastern Time and is now available
on STAAR's website at www.staar.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before we get started, let me quickly remind you that during
the course of this conference call the Company will make forward-looking statements. We caution you that any statement that is
not a statement of historical fact is a forward-looking statement. This includes remarks about the Company's projections, expectations,
plans, beliefs and prospects. These statements are based on judgement and analysis as of the date of this conference call and are
subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference
call and webcast are described in the Safe Harbor statement in today's press release, as well as STAAR's public periodic filings
with the SEC. STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes
and does not intend to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, to supplement the GAAP numbers, we have provided
non-GAAP adjusted net income and diluted net income per-share information. We believe that these non-GAAP numbers provide meaningful
supplemental information and are helpful in assessing our historical and future performance. Also, in order to compare our performance
from period-to-period without the effect of currency fluctuations, we apply the same average exchange rate application to the prior
period, or constant currency rate to sales. A table reconciling the GAAP information to the non-GAAP information is included in
today's financial release, which is available on our website. Now, I would like to turn the call over to Caren Mason, President
and Chief Executive Officer of STAAR Surgical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ Thank you, Brian, and good afternoon, everyone.
I will begin our discussion with general commentary on the state of the business. Steve will then review key third quarter fiscal
year 2015 financial results before we open the call for your questions. When I first joined STAAR's board of directors in June
of 2014, I was a bit skeptical and encouraged to make my way to London to experience an extraordinary experts meeting and European
Congress. As it turned out, I was unable to clear my schedule to attend. This year, although no longer skeptical, I was still unsure
about the designation of extraordinary. Before this year's experts and ESCRS meetings in Barcelona, we welcomed Dr. John Hayashida
and Dr. Keith Holliday to STAAR, who head our Clinical and Medical Affairs and R&amp;D departments, respectively. The timing was
good in that they are both ophthalmic industry veterans and they were anxious to attend and learn and properly position the significance
of this meeting and the takeaways in their planning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As it turns out, all three of us were stunned by the exceptional
and very unique commitments by leading surgeons to share the ICL's superlatives and challenges with each other, and any surgeon
willing to engage at the experts meeting, at the ESCRS, and at working group special sessions we conducted. At the experts meeting
topics included: Over two decades of ICL-proven safety; Collamer, a Unique Material for Long-term Safety; literature review of
Visian ICL safety, long-term clinical outcomes of the Visian ICL; Clinical Grand Rounds, Learning from my Mistakes and Challenging
Cases. At the ESCRS, between educational symposia, training and instructional courses, posters and papers, there were over 40 opportunities
to learn about the ICL at the ESCRS. Topics there included 20 Years of Preserving the Cornea for the Future; Correcting Astigmatism
in Today's Refractive Practice; Visian ICL Selection Criteria and Preoperative Examination and Planning; and Visian ICL Surgical
Technique and Postoperative Care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the working groups combined, over 20 leading surgeons debated
for several hours the merits of potential ICL presbyopic correction parameters and sizing for the ICL and its relative significance
and successful placement. Having the attention and attendance of leading surgeons in various venues for multiple days and evenings
was a feat I have never witnessed. Our verdict is that extraordinary to characterize these combined events is an understatement.
Much of what we learned is being put into planning and practice just one month later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The clear challenge for STAAR is to apply these tenets of wisdom
and deep appreciation for this technology to a much larger global user base. This is where we are focused. We have significant
work to do in each market to properly position our vision care solutions as productive and profitable practice additions for the
surgeon while delivering the best possible outcomes for patients. The technology is proven and performing. The uptake this quarter
in usage is very promising but not yet a predicate for base business certainty. We do not collectively believe that the ICL, whatever
vision correction classification we offer, is an outlier or secondary solution to other refractive procedures. However, today it
accounts for less than 10% of refractive surgery in the majority of practices. We believe that the promise of the ICL is as fresh
as when it was introduced. The market building and foundational operational excellence needs to be applied and achieved. In that
vein, we have completed a number of deliverables we talked about beginning in April.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA remediation and improvement of our quality system continues,
and is achieving internal metrics and budget projections. We have begun the transition from a strong contingent of consultant support
to the hiring of several new quality leaders including a vice president of global quality assurance, quality systems managers,
principal quality engineers, microbiology quality engineers, quality system auditors, and quality control inspectors. We continue
to fund the remediation and significant executive and staff additions, QMS systems, facilities and equipment monitoring upgrades
from operating capital. We place significant performance criteria on cash generation, and in the second quarter added $800,000
in cash followed by cash generation in the third quarter of $1.1 million. We have added global strategic marketing to lead our
market building. We have adopted a much stronger project management focus for the addition of a more rigorous phase review discipline
which will be in place by year-end. We have created a clinical affairs department led by industry-recognized leaders, both on staff
and supporting us on a consultative basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Every aspect of our current commitment to regulatory bodies
and future opportunities for clinical studies and validation is being reviewed and plans solidified. We have hired the very talented
and accomplished Dr. Keith Holliday as leader of research and development. His initial focus is on supporting our remediation work,
presbyopic ICL development, material and visionary projects, and new categories that blends development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have selected and recruited clinically leading surgeons to
serve on our working groups for special projects, including presbyopia. We have completed our intellectual property patent (inaudible)
review and filing new applications for recent developments is underway. Our plans to introduce the new expanded optic CentraFLOW
lens are on schedule for targeted introduction beginning in Europe in Q1 2016, pending review and approval of the CE mark submission.
We are finalizing a new branding strategy for this lens with a goal of increasing the appeal of the Visian ICL, the surgeons and
their millennial patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All in all, I am pleased with the strength and commitment of
the team to deliver ever-improving results for our shareholders. We need to rebuild, repurpose and reposition both operationally
and commercially. We believe Implantable Collamer lenses will provide an integral evolution to visual freedom for patients all
over the world. I will now turn over the call to Steve for a review of our Q3 financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Brown^ Thank you, Caren, and good afternoon, everyone.
I will start the financial overview with top line results by product and market. First, for our ICL product line, total sales were
$12.9 million for the third quarter of 2015, increasing by 21% from the prior year period with units increasing 21% as well. We
experienced strong performance with sales and units increasing by double-digits in each regional market. EMEA ICL sales were $4.8
million during the third quarter, an increase of 25% compared to the prior year period with strong unit growth of 37%. Sales in
Germany tripled over the prior year period due to the conversion of the market from the former distributor to direct selling, which
began July 1, 2015, and increased unit growth of 44%. The increase in average selling price in Germany offset approximately one-third
of the $1.1 million impact on EMEA sales from the weakening of the euro against the US dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In other key markets, EMEA unit sales were similarly strong
with the Middle East up 67%, France up 38%, Latin America up 33%, and Spain up 16%. Asia-Pacific ICL sales were $6.4 million during
the third quarter, an increase of 21% compared to the prior year period, with unit growth of 13%. Korea ICL sales increased 54%
compared to the prior year period, when sales were first impacted by negative LASIK media coverage. Korea sales continue to recover
as September year-to-date sales are now 7% behind prior year compared to being 21% behind the prior year through June. China ICL
sales increased 20% due to the adoption of the CentraFLOW technology introduced in December 2014, and a price increase of 4% in
July 2015. North America ICL sales were $1.7 million during the third quarter, up 14% from the prior year period, with unit growth
of 10%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For our IOL product line, total IOL sales were $4.4 million
for the third quarter of 2015, and down 24% from the prior year period, with units down 18%. The decline was due to the weakening
yen affecting Japan sales, the weakening euro affecting France sales, and a planned phase-out of sales in China; a planned hold
on sales in Germany due to the distributor-to-direct conversion, and a continued decline in the US. In Japan, where we have over
half our IOL business, units increased 5%. So, cumulatively, for the third quarter of 2015, our sales were $18.8 million, an increase
of 3% from the $18.2 million of sales reported in the third quarter of 2014. In constant currency sales increased 7%. The total
currency impact on sales from the strengthening US dollar against the euro and the yen was $1.8 million in the quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Turning the discussion now to margins and spending, our gross
margin improved 300 basis points to 68.3% compared to the prior year period of 65.3%. This improvement resulted from favorable
geographic and product mix of 221 basis points, lower average unit costs of 131 basis points, higher average selling prices of
73 basis points, exclusive of the impact of the weaker euro on average selling prices, and lower other cost of sales of 22 basis
points. The impact of the euro was unfavorable by 140 basis points.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third quarter operating expenses increased 10% to $14.8 million
compared to $13.4 million in the prior year period due to a bonus accrual reversal of $1.6 million in the prior year period. General
and administrative expense was $4.9 million and approximately flat to the prior year when adjusting for the bonus accrual reversal.
Marketing and selling expense was $6.3 million, and approximately $740,000 lower than the prior year due to optimization, North
American selling and promotion cost, and decreased selling and promotional costs in Japan, and partially offset by increased selling
costs in Germany as a result of the conversion to a direct sales force in that market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expense, which includes remediation
and other FDA expenses, was $3.7 million and approximately $550,000 higher than the prior year due to increased validation and
remediation expense. Remediation expense for the first nine months of 2015 is on budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Turning our attention to the bottom line, the net loss for the
third quarter of 2015 was $1.8 million, or $0.04 on a per-diluted share basis compared to a net loss of $2.7 million, or $0.07
on a per-diluted share basis in the third quarter of 2014. The lower net loss in the third quarter 2015 versus the prior year period
was primarily due to higher gross profit from sales volume and improved sales mix, higher other income and expense, and a lower
income tax provision partially offset by higher operating expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On a non-GAAP basis, the adjusted net loss for the quarter was
$40,000, or break-even on a per-diluted share basis as compared to adjusted net income in the prior year period of $87,000, or
break-even per diluted share. These adjusted figures exclude nonrecurring expenses such as manufacturing consolidation and FDA
remediation, as well as gains and losses on foreign currency transactions and stock-based compensation costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Now, turning to the balance sheet, cash and cash equivalents
at October 2, 2015 totaled $16.1 million compared to $15.3 million at the end of the second quarter of 2015, and $13 million at
the end of 2014. The Company added $746,000 in cash during the third quarter of 2015, which includes $1.1 million provided by operating
activity, and $253,000 from the exercise of stock option partially offset by $595,000 in other uses of cash, primarily purchases
of property and equipment. This concludes my comments and with that we are ready to take your questions. Operator, please open
the line for questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+++ q-and-a</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operator^ (Operator Instructions) Our first question comes from
Chris Cooley from Stephens. Your line is open</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Cooley^ Just two for me and I'll hop in the queue. One,
very impressive growth there on the ICL during the quarter. Congratulations on that. Could you tell us if there were any new relationships
that might have contributed to any of your international growth during the quarter? And then as a follow-on, in you prior call
you had hinted about evaluating or restructuring the cataract business broadly defined, noticing that it's weak again here, admittedly
a lot of that due to currency. But could you maybe update us on your thoughts as it pertains to the cataract segment of your business
as well? Thanks so much.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ Sure, Chris. With regard to ICL growth, there wasn't
one significant large account that would account, for example, let's say multiple markets of growth. What there was during the
third quarter, I believe, is a renewed confidence by our distributors and by our surgeons and our ability to deliver on time. You
saw that the Toric ICL in the third quarter beat the record of the second quarter. So, none of this growth could really be attributed
to unusual levels of buying or stocking. So, this is very, very healthy growth trend-wise. Current customers, some new customers,
new surgeons in all of our markets, excited about the ICL and certainly the CentraFLOW and its proven performance. We do believe
some if it came from a very outstanding experience at our experts meeting, where 50% of the surgeons who attended to learn very
in-depth understanding of our ICL products were new to that meeting. So, I think from the ICL standpoint we have very healthy growth
with our large business opportunities currently in development and underway, but not contributing as of yet to the current ICL
growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In terms of the IOL, we are really going in 2016, we're going
to address the premium IOL market, what segments we currently address in the major markets. Mostly today, as you know, we have
a growth story in Japan. We have some business in Europe that is healthy. We had a reduction in business in Germany. There may
be some opportunity for us to win some of that back going direct. And there is also certainly the business in the US, and that
business, of course, is handled by our manufacturing representative group. So, for us, when we look at the competitiveness of the
IOL, we look at directionally where IOL is going in terms of being premium, of presbyopic correction outside the US being promised,
it makes us take a very hard look at how we want to participate and compete. Our Collamer material, by the way, could be in consideration
for a presbyopic IOL in the future, so all of the above is under consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Cooley^ Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operator^ (Operator Instructions) Our next question comes from
Jim Sidoti from Sidoti.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ I know on the last call you mentioned that price
increase was going to start to take effect around now. Do you think there was some buying ahead of that in the quarter?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Brown^ Hi, Jim, this is Steve. We did a thorough analysis
of it and the only buy-in was in the markets in the Middle East, where we had the largest price increase. That buy-in was only
about 10% of their normal quarterly purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ Okay, so no significant stocking ahead of the price
increase?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Brown^ No, there was not. And if you remember, Jim, we
mentioned on the last call, for Toric ICLs there can be no stocking, because you order those lenses for a patient-specific eye.
And in our two largest markets where the Spherical ICL could be stocked, China and Korea, China, there was already a price increase
that took place, and in Korea we were not doing yet a price increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ Right. Can you give us an update on Korea? I know
a year ago is when the negative (inaudible) came out and you were going to start some direct to consumer advertising. Can you let
us know what the environment there is like now?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ Sure. I have had the opportunity to meet with our
Korean distributor in Lisbon and Barcelona and we remain in contact. He tells us that in this past quarter, as you may have seen,
South Korea from a consumer basis has started to pick up again. People are out and about, they're probably making up for lost time
with the isolation around MERS. In terms of the LASIK business in Korea, I won't comment there in terms of any recovery, but will
tell you that more normal buying patterns are what we are experiencing right now from our Korean distributor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ All right. And then China, can you just expand on
why you decided to exit that market for IOLs?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Brown^ Yes. We just didn't have the size to make sense
of the sale in China. There is a lot to cover and being that we were selling through distributors, the profitability of selling
IOLs in that market just was not up to snuff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ Okay. How about back at the factory, do you think
all the manufacturing issues have been worked out now? Do you have enough capacity to respond to the typical pickup in the fourth
quarter?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Brown: We have enough capacity to respond to an uptake.
If you recall, coming out of the second quarter, we had a significantly reduced, our backorders coming out of the third quarter.
There is an insignificant number of backorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ Right. And then, finally, I know you're reluctant
to update us on the FDA, but I assume there has been continuous back-and-forth with the FDA, and have any of the 483s from last
year and earlier this year been resolved?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ There has really been one-way communication to
the FDA since February, with our initial response to both the warning letters and 483 observations in terms of what our plan would
be for remediation, and a complete overhaul of our quality system and a building a culture of quality. What we do and when we said
we met our internal metrics, it means that all the promises that we made to the FDA in terms of what we would deliver and when
is largely on track, and that in terms of the remediation dollars that we've allocated over and above their incrementals to our
normal spending are on plan. So, we continue to do what we promised to do and we have had some consultative support in terms of
taking a look at our progress, and we continue to adjust along the way to make sure that we are very closely and adeptly meeting
what the expectations would be for us to get back into full compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ And, Caren, now that you've been there for, well,
I guess about six months or so, do you think that STAAR can be a profitable company without a Toric approval in the US?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ Well, actually, if you were to do some adjusting
right now, you would find us already profitable in the fact that if you take out the incremental spending of $1 million a quarter,
if you add in some of the currency challenges that we have, and you take a look at the hold on spending and what we've been able
to do, you would have a profitable picture already today. So, yes, I absolutely believe this Company can be profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Sidoti^ All right. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operator^ At this time I'm showing no further questions. I would
like to turn the call back over to Ms. Caren Mason, President and CEO of STAAR Surgical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ I think there might be someone on the line, if
you could double-check, please?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operator^ We do have a question now from Brian Weinstein from
William Blair. Your line is open.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matt Larew^ Hey, good afternoon. This is Matt Larew in for Brian.
I appreciate you taking me in here at the end. First one, Caren, you know that the second quarter here where you discussed a multitude
of constructive initiatives you are taking to address quality, manufacturing, I was wondering if we could get a sense of what stage
you're in in terms of transitioning from the evaluation and consultancy stage into the hiring and actual action phases of some
of those programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ Okay. In terms of consultants, it's really been
totally the quality and regulatory side because of the massive commitment that we made and the time frame to do it, and a lot of
those jobs, we, I think, are down to six consultants from a much larger grouping. We've hired from that consulting group as well
as outside some really outstanding talent that have become employees. In terms of all our other major initiatives, consultants
are really not involved. These are our internal people and we made some good hires there as well. So, in every one of those major
initiatives that we've been addressing, we are meeting or exceeding our timelines in terms of what we expect for performance and
for return on that investment in 2016 and beyond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matt Larew^ Okay, thanks, Caren. And, Steve, one for you. I
think you said that 71 basis points of the gross margin impact came from some of the higher SPs in the third quarter there. Just
curious what percentage of market you already converted over to the higher SP versus those that were going to take effect on October
1?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Brown^ Oh, yes. The higher average selling prices, in
terms of gross profit margin, that was an add of 73 basis points. But the price increases took place October 1. So, those higher
average selling prices didn't have anything to do with the price increase other than the one we took in China in July.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Matt Larew^ Got it, thanks. That's all for me. Appreciate it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operator^ At this time I would like to turn the call back over
to Ms. Caren Mason, President and CEO of STAAR Surgical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caren Mason^ Thank you for your participation on our call today.
We appreciate your interest and investment in our Company. We look forward to seeing some of you at the Stephens conference in
New York City on November 10. All the best to all of you.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
